Thomas Fabre
Cambridge, Massachusetts, United States
693 followers
500+ connections
About
Principal scientist in the fibrosis and innate immunity team
Activity
-
Join us for the best fibrosis and tissue repair conference! Amazing line up, people and location. 👇👇👇
Join us for the best fibrosis and tissue repair conference! Amazing line up, people and location. 👇👇👇
Shared by Thomas Fabre
-
It is a great pleasure to share our recent review article about the role of type 3 cytokines in MASLD. Congrats Mohamed Abdelnabi and Ghada Hassan
It is a great pleasure to share our recent review article about the role of type 3 cytokines in MASLD. Congrats Mohamed Abdelnabi and Ghada Hassan
Liked by Thomas Fabre
-
Imagine being the mother of one of these boys - in the stadium and twitching and praying with every flip and turn throughout every routine🙄🤣❤️…
Imagine being the mother of one of these boys - in the stadium and twitching and praying with every flip and turn throughout every routine🙄🤣❤️…
Liked by Thomas Fabre
Experience
Education
Publications
-
IL-17A Enhances the Expression of Profibrotic Genes through Upregulation of the TGF-β Receptor on Hepatic Stellate Cells in a JNK-Dependent Manner
Journal of Immunology
IL-17 producing cells, known as Th17 cells were implicated in several inflammatory conditions of the gut including liver fibrosis. In this paper, we demonstrate a potential mechanism for the role of IL-17 in enhancing liver fibrosis using an in vitro model of fibrosis through stimulation of the human hepatic stellate cell (HSC) line (LX2) and primary HSCs. We demonstrate that IL-17 alone has no direct effect on expression of the fibrogenic genes but increases their sensitivity to lower doses of…
IL-17 producing cells, known as Th17 cells were implicated in several inflammatory conditions of the gut including liver fibrosis. In this paper, we demonstrate a potential mechanism for the role of IL-17 in enhancing liver fibrosis using an in vitro model of fibrosis through stimulation of the human hepatic stellate cell (HSC) line (LX2) and primary HSCs. We demonstrate that IL-17 alone has no direct effect on expression of the fibrogenic genes but increases their sensitivity to lower doses of the fibrogenic cytokine TGF-beta by upregulating and stabilizing the TGF-beta receptor on the surface of HSCs. More work examining the in vivo relevance of this observation is on going.
Other authorsSee publication -
Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C
PloS Pathogens
n this study, we investigated the mechanisms underlying failure of the CD4 helper T cell response during acute hepatitis C infection. We demonstrate that this failure is primarily due to loss of IL-21-producing CD4 T cells in individuals who progress towards chronic infection. This is accompanied by exhaustion of virus-specific cytotoxic CD8 T cells through upregulation of the exhaustion markers Tim-3, PD-1 and CTLA-4, higher plasma levels of the Tim-3 ligand Galectin-9 (Gal-9) and increased…
n this study, we investigated the mechanisms underlying failure of the CD4 helper T cell response during acute hepatitis C infection. We demonstrate that this failure is primarily due to loss of IL-21-producing CD4 T cells in individuals who progress towards chronic infection. This is accompanied by exhaustion of virus-specific cytotoxic CD8 T cells through upregulation of the exhaustion markers Tim-3, PD-1 and CTLA-4, higher plasma levels of the Tim-3 ligand Galectin-9 (Gal-9) and increased frequency of Gal-9 producing regulatory T cells (Tregs). In vitro supplementation with IL-21 rescued HCV-specific CD8 T cells from Gal-9 induced apoptosis. Blocking Gal-9 expression in Tregs restored IL-21 production by virus-specific CD4 helper T cells. Altogether, our results suggest that failure of CD4 T cell help during acute HCV may be partially meditated by an imbalance between IL-21-producing CD4 T cells and Treg cells whereby exhaustion of both CD4 and CD8 T cells through the Tim-3/Gal-9 pathway is counteracted by IL-21.
Other authorsSee publication -
IL28B SNP Screening and Distribution in the French Canadian Population Using A Rapid PCR-based Test
Immunogenetics (In Press)
Jean-François Gélinas1,*, Thomas Fabre1,2, Philippe Willems1, Reynold C. Leung3, Jacob
George3, Bernard Willems1,4, Julie Bruneau1,5 and Naglaa H. Shoukry1,4,†Other authorsSee publication
Honors & Awards
-
CIHR Gold medal
CIHR
Award for best presentation (Gold), 500CAD
-
CIHR Gold medal for best poster presentation
CIHR
500CAD
-
CIHR Ph.D fellowship
CIHR
35000CAD/yr
-
FRQS Ph.D fellowship
FRQS
Declined, ranked 1st.
-
Award for best poster- University of Montréal
Université de Montréal
150dollars
-
Bourse Ph.D du CRCHUM
CRCHUM
1000CAD
-
NCRTP Fellowship
National CIHR Research Training Program (NCRTP) in Hepatitis C
Annually, the NCRTP-HepC extends awards to provide transdisciplinary training and stipend support to both Canadian and foreign individuals involved with hepatitis C research, who are university graduates at various stages of their academic and professional career. This program and the stipends it provides are meant to further trainees' knowledge and understanding of hepatitis C.
23000CAD/year -
Premier prix pour présentation par affiche
CRCHUM
400dollars
-
Premier prix pour présentation orale
FRSQ réseau SIDA/Mi
500dollars
-
Troisiéme prix pour présentation orale
FRSQ réseau SIDA/Mi
150dollars
-
Bourse d'excellence de la FESP
Faculté des études supérieures
Financement de juin 2011 à juin 2012
-
Bourse d'excellence fondation Gabriel le marquis
Fondation Gabriel le marquis
Financement de juin 2011 à juin 2012
Languages
-
Français
Native or bilingual proficiency
-
Anglais
Full professional proficiency
-
Espagnol
Elementary proficiency
More activity by Thomas
-
Proud father today. My daughters first poster - and it’s on integrin expression :) Lola Byrne
Proud father today. My daughters first poster - and it’s on integrin expression :) Lola Byrne
Liked by Thomas Fabre
-
See you there, if you want to learn more about the myeloid cell "mess" and how to target it in fibrotic diseases.
See you there, if you want to learn more about the myeloid cell "mess" and how to target it in fibrotic diseases.
Shared by Thomas Fabre
-
📣 With 𝗹𝗲𝘀𝘀 𝘁𝗵𝗮𝗻 𝟮 𝘄𝗲𝗲𝗸𝘀 𝘁𝗼 𝗴𝗼, limited places remain for the 𝟴𝘁𝗵 𝗜𝗣𝗙 𝗦𝘂𝗺𝗺𝗶𝘁 (August 20-22, Boston). This gathering…
📣 With 𝗹𝗲𝘀𝘀 𝘁𝗵𝗮𝗻 𝟮 𝘄𝗲𝗲𝗸𝘀 𝘁𝗼 𝗴𝗼, limited places remain for the 𝟴𝘁𝗵 𝗜𝗣𝗙 𝗦𝘂𝗺𝗺𝗶𝘁 (August 20-22, Boston). This gathering…
Liked by Thomas Fabre
-
Morphic today announced it has entered into an agreement to be acquired by Eli Lilly and Company (“Lilly”) in an all-cash transaction valued at…
Morphic today announced it has entered into an agreement to be acquired by Eli Lilly and Company (“Lilly”) in an all-cash transaction valued at…
Liked by Thomas Fabre
-
🎉 I’m proud of what we accomplished together, It was a true team effort. A huge thank you to everyone involved for their hard work, dedication, and…
🎉 I’m proud of what we accomplished together, It was a true team effort. A huge thank you to everyone involved for their hard work, dedication, and…
Liked by Thomas Fabre
-
I am thrilled to share the exciting news! My abstract, “Fibrosis Regression and ECM Remodeling,” was recently selected for an Oral Presentation at…
I am thrilled to share the exciting news! My abstract, “Fibrosis Regression and ECM Remodeling,” was recently selected for an Oral Presentation at…
Liked by Thomas Fabre
-
Our group is growing! Join us in developing new drugs for neuroinflammation. Take a look at the posting! https://lnkd.in/e6y5fJFu
Our group is growing! Join us in developing new drugs for neuroinflammation. Take a look at the posting! https://lnkd.in/e6y5fJFu
Liked by Thomas Fabre
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Thomas Fabre in United States
4 others named Thomas Fabre in United States are on LinkedIn
See others named Thomas Fabre